BioLife Solutions (NASDAQ:BLFS) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of BioLife Solutions (NASDAQ:BLFSGet Rating) to a sell rating in a research note published on Monday morning.

Other analysts also recently issued reports about the company. Cowen decreased their price target on BioLife Solutions to $29.00 in a research report on Monday, August 15th. Stephens decreased their price target on BioLife Solutions to $31.00 in a research report on Wednesday, November 16th.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $21.01 on Monday. The company has a market cap of $898.51 million, a PE ratio of -8.47 and a beta of 1.78. BioLife Solutions has a 52 week low of $10.40 and a 52 week high of $50.70. The business has a 50 day moving average price of $22.21 and a 200-day moving average price of $19.18. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, COO Greef Roderick De sold 8,552 shares of the stock in a transaction on Friday, October 7th. The stock was sold at an average price of $22.69, for a total transaction of $194,044.88. Following the completion of the transaction, the chief operating officer now directly owns 116,719 shares of the company’s stock, valued at $2,648,354.11. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Amy Duross sold 2,600 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $24.35, for a total value of $63,310.00. Following the completion of the transaction, the director now directly owns 18,157 shares of the company’s stock, valued at $442,122.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Greef Roderick De sold 8,552 shares of the firm’s stock in a transaction on Friday, October 7th. The stock was sold at an average price of $22.69, for a total value of $194,044.88. Following the completion of the transaction, the chief operating officer now directly owns 116,719 shares of the company’s stock, valued at $2,648,354.11. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,861 shares of company stock valued at $930,969. Company insiders own 3.30% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

Large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC boosted its holdings in shares of BioLife Solutions by 802.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,218 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 1,083 shares during the period. Wipfli Financial Advisors LLC bought a new position in shares of BioLife Solutions in the third quarter worth $29,000. Nisa Investment Advisors LLC boosted its stake in BioLife Solutions by 439.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 1,230 shares during the period. Point72 Hong Kong Ltd bought a new stake in BioLife Solutions during the first quarter valued at $36,000. Finally, Lazard Asset Management LLC bought a new stake in BioLife Solutions during the first quarter valued at $45,000. 86.69% of the stock is owned by institutional investors.

BioLife Solutions Company Profile

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Recommended Stories

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.